Marta Pestrin
Overview
Explore the profile of Marta Pestrin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
669
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scandino R, Nardone A, Casiraghi N, Galardi F, Genovese M, Romagnoli D, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):25.
PMID: 40057527
Cell-free DNA (cfDNA) extracted from peripheral blood has emerged as a crucial biomarker source in oncology research. To enhance the detection of somatic copy number alterations (SCNAs) and circulating tumor...
2.
Romagnoli D, Nardone A, Galardi F, Paoli M, De Luca F, Biagioni C, et al.
Brief Bioinform
. 2023 Jan;
24(2).
PMID: 36653909
DNA-methylation alterations are common in cancer and display unique characteristics that make them ideal markers for tumor quantification and classification. Here we present MIMESIS, a computational framework exploiting minimal DNA-methylation...
3.
Fontanella C, Giorgi C, Russo S, Angelini S, Nicolardi L, Giarratano T, et al.
Crit Rev Oncol Hematol
. 2022 Oct;
180:103848.
PMID: 36257536
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are now a backbone of treatment for hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. CDK4/6i plus...
4.
Sanna G, Pestrin M, Moretti E, Biagioni C, De Santo I, Gabellini S, et al.
Clin Breast Cancer
. 2020 Dec;
21(4):e332-e339.
PMID: 33353853
Background: Metronomic chemotherapy can induce disease control in patients with metastatic breast cancer (MBC) and has better safety profiles than conventional chemotherapy. Evidence suggests that cytotoxics can be anti-angiogenic in...
5.
Barchiesi G, McCartney A, Biagioni C, Siclari O, Rossi L, Pestrin M, et al.
Breast J
. 2019 Jul;
25(6):1225-1229.
PMID: 31310384
Overall survival (OS), disease-free survival (DFS), and distant recurrence-free interval (DRFI) were evaluated from 169 patients diagnosed with early triple negative breast cancer. Overall, 5 and 10 years OS, DFS,...
6.
Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, et al.
Breast Cancer Res
. 2019 May;
21(1):71.
PMID: 31142370
Currently, there is limited data regarding the effectiveness of standard subsequent line therapies such as endocrine therapy, chemotherapy, or targeted agents after progression on CDK4/6 inhibitor-based regimens. This paper describes...
7.
McCartney A, Biagioni C, Schiavon G, Bergqvist M, Mattsson K, Migliaccio I, et al.
Eur J Cancer
. 2019 May;
114:55-66.
PMID: 31059974
Background: Thymidine kinase 1 (TK1) plays a critical role in DNA synthesis and cell proliferation. Recent studies have shown potential for serum TK1 activity (sTKa) as a prognostic marker and...
8.
Rossi L, Biagioni C, McCartney A, Moretti E, Pestrin M, Sanna G, et al.
Anticancer Res
. 2018 Aug;
38(8):4839-4845.
PMID: 30061257
Background: The combination of platinum with 5-fluorouracil has scarcely been studied in metastatic breast cancer. As this combination does not lead to significant hepatic metabolism, in some clinical situations it...
9.
McCartney A, Moretti E, Sanna G, Pestrin M, Risi E, Malorni L, et al.
Ther Adv Med Oncol
. 2018 Jun;
10:1758835918776925.
PMID: 29899762
Until recently, the mainstay of treatment in the majority of hormone receptor (HR)-positive, human epidermal growth factor 2 receptor (HER2)-negative advanced breast cancer (ABC) has consisted of single-agent endocrine therapy...
10.
Bonechi M, Galardi F, Biagioni C, De Luca F, Bergqvist M, Neumuller M, et al.
Oncotarget
. 2018 Apr;
9(23):16389-16399.
PMID: 29662653
The aim of this study was to investigate if thymidine kinase-1 (TK1), a well-known proliferation marker, could represent a valid circulating biomarker to identify hormone receptor positive (HR+)/HER2 negative (HER2neg)...